Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06343311 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Study acronym: STARLIGHT-1
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Dec 31, 2026 → Jul 31, 2027
Primary endpoints removed 4 → 2 primary endpoints
See other at-risk trials from Estrella Immunopharma, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Jul 31, 2027 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Lead sponsor: Estrella Biopharma, Inc. to Estrella Immunopharma, Inc.
    • Enrollment increased: 21 → 27 participants
    • Trial sites expanded: 2 → 5 locations
    • Study completion pushed from Dec 31, 2027 to Jul 31, 2028
    • Eligibility criteria expanded, about 209 words
    • Secondary endpoints revised (9)
    • Study description expanded, about 41 words
  2. Study sites: 1 to 2v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 15, 2024 to Jun 1, 2024
    v5
  4. Start date: May 15, 2024 to Jun 15, 2024v4
  5. Re-verified, no change to tracked fieldsv3
  6. Start date: Mar 31, 2024 to May 15, 2024
    • Eligibility criteria expanded, about 85 words
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.
Trial Details
NCT Number NCT06343311
Lead Sponsor Estrella Immunopharma, Inc.
Collaborators: Eureka Therapeutics Inc.
Conditions
(from sponsor)		 B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma +7 more
Related terms Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Primary Effusion
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov